Encinitas, CA, United States of America

Tim Gahman


Average Co-Inventor Count = 17.0

ph-index = 3

Forward Citations = 69(Granted Patents)


Company Filing History:


Years Active: 2005-2006

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Tim Gahman: Innovator in Nuclear Receptor Binding Compounds

Introduction

Tim Gahman is a notable inventor based in Encinitas, CA (US). He has made significant contributions to the field of nuclear receptor binding compounds, holding a total of 3 patents. His work focuses on developing compounds that interact with nuclear receptors, which are crucial in various biological processes.

Latest Patents

Gahman's latest patents include innovative compounds that bind to the FXR NR1H4 nuclear receptor. The first patent describes compounds that act as agonists, antagonists, or mixed agonists/antagonists of the NRH receptor. This invention provides methods for treating diseases and conditions through the binding of the nuclear receptor by these compounds. The second patent relates to compounds that bind to the NR1H4 nuclear receptor, functioning as agonists and antagonists. This invention also addresses the treatment of diseases and conditions through the binding of the nuclear receptor.

Career Highlights

Throughout his career, Tim Gahman has worked with prominent companies in the pharmaceutical industry, including Phenex Pharmaceuticals AG. His expertise in nuclear receptor research has positioned him as a valuable contributor to advancements in medicinal chemistry.

Collaborations

Gahman has collaborated with notable professionals in his field, including Ulrike Bauer and Zach Cheruvallath. Their combined efforts have furthered research and development in nuclear receptor binding compounds.

Conclusion

Tim Gahman's innovative work in nuclear receptor binding compounds has made a significant impact in the field of medicinal chemistry. His contributions continue to pave the way for new treatments and therapies.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…